Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SyStemix moves to avert cash crunch

Facing up to its pending need for cash, and lacking optimism about the equity markets, SyStemix Inc. turned to partner Sandoz AG for an $80 million infusion.

The deal

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE